TrialPath
Recruiting

Regulation of Inflammatory Genes in Psoriasis

NCT03125655 · University of Alabama at Birmingham
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.
Eligibility criteria
Inclusion Criteria: * Clinical diagnosis of psoriasis * Must be age 19 or older. * Must be Fitzpatrick skin type I, II, III, IV, V, VI. Exclusion Criteria: * Subjects who do not have photosensitive disease and are not on photosensitizing medications. * Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy). * Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants. * Subjects who are pregnant.
Study design
Enrollment target: 13 participants
Age groups: adult, older_adult
Timeline
Starts: 2014-04-22
Estimated completion: 2028-04-28
Last updated: 2026-04-06
Interventions
Diagnostic Test: Inflammatory markers
Primary outcomes
  • • Inflammatory genes (1 day)
Sponsor
University of Alabama at Birmingham · other
All locations (1)
The Kirklin ClinicRecruiting
Birmingham, Alabama, United States
Regulation of Inflammatory Genes in Psoriasis · TrialPath